

Global PD-1 and PD-L1 Inhibitors Market: Size, Trends & Forecasts (2018-2022)

August 2018



Global PD-1 and PD-L1 Inhibitors Market: Coverage

Executive Summary and Scope

Introduction/Market Overview

Global Market Analysis

Regional Market Analysis

Dynamics

Competitive Landscape

Company Profiling

Global PD-1 and PD-L1 Inhibitors Market: Coverage

Scope of the Report

Attributes	Details
Title	Global PD-1 and PD-L1 Inhibitors Market: Size, Trends & Forecasts (2018-2022)
Coverage	Global and Regional
Regional Coverage	China, The US, ROW
Market Influencing Variables	Growth Drivers, Challenges, Market Trends
Forecast Period of Market	2018-2022
Competition in the Market	Dominated
Key Players	Bristol-Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd., BeiGene, Ltd.

Global PD-1 and PD-L1 Inhibitors Market

Executive Summary

Cancer is the fastest growing disease across the world and one of the most important development in the field of cancer treatment is the introduction of immune checkpoint inhibitors-agents that help to stimulate the immune system. The two main cancer treatment approaches are: Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors. PD-1 and PD-L1 inhibitors are both found on the surface of the cancer cells and used to kill cancer cells.


The drugs approved as a PD-1 inhibitor are Pembrolizumab and Nivolumab and the drugs approved as a PD-L1 inhibitors are atezolizumab, Durvalumab and Avelumab. There are various PD-1 and PD-L1 inhibitors which are still in experimental phase of development. The adverse effects of PD-1 and PD-L1 inhibitors are pneumonitis, colitis, skin reactions, immune thrombocytopenia, cardiac insufficiency, diarrhea, pruritus, myocarditis and pneumonitis.

PD-1 and PD-L1 inhibitors has a long history with continuously evolving new generation PD-1 and PD-L1 inhibitors. The PD-1 and PD-L1 inhibitors market can be segmented on the basis of type, indications, drug and distribution channel.

The global PD-1 and PD-L1 inhibitors market has increased at a significant annual growth rate during the years 2016-2017 and projections are made that the market would rise in the next four years i.e. 2018-2022 tremendously. The PD-1 and PD-L1 inhibitors market is expected to increase due to aging population, growth in GNI per capita, growing urban population, increasing incidence of certain types of cancer, rise in the number of people with cancer, etc. Yet the market faces some challenges such as high cost of oncology treatment, side effects and toxicity, failure of clinical trials, time consuming and uncertain regulatory process, etc.


Global PD-1 and PD-L1 Inhibitors Market

Market Overview



PD-1 and PD-L1 Inhibitors Market: Global Analysis


Global PD-1 and PD-L1 Inhibitors Market by Value




The global PD-1 and PD-L1 Inhibitors market, valued at US\$.... billion in 2017, increased as compared to US\$... billion in 2016 at an annual growth rate of% from 2016 to 2017. The global PD-1 and PD-L1 Inhibitors market is anticipated to reach up to US\$... billion by 2022 from US\$... billion in 2018..

PD-1 and PD-L1 Inhibitors Market: Global Analysis

Global PD-1 and PD-L1 Inhibitors Market by Region;
2017-2018




Global PD-1 and PD-L1 Inhibitors Market by Segments;
2017




Segments	Share
Metastatic	xx%
Adjuvant	xx%

PD-1 and PD-L1 Inhibitors Market: Segment Analysis

Metastatic PD-1 and PD-L1 Inhibitors Market by Value




Adjuvant PD-1 and PD-L1 Inhibitors Market by Value




Segments	CAGR
	2018-2022
Metastatic PD-1 and PD-L1 Inhibitors	xx%
Adjuvant PD-1 and PD-L1 Inhibitors	xx%

PD-1 and PD-L1 Inhibitors Market: Regional Analysis


The US PD-1 and PD-L1 Inhibitors Market by Value



China PD-1 and PD-L1 Inhibitors Market by Value



ROW PD-1 and PD-L1 Inhibitors Market by Value



Region	CAGR
	2018-2022
The US	xx%
China	xx%
ROW	xx%

PD-1 and PD-L1 Inhibitors Market: China Analysis

**China PD-1 and PD-L1 Inhibitors Market by Cancer;
2018 & 2022**



Cancer	Share
Non-small Cell Lung Cancer	xx%
Hepatocellular Carcinoma	xx%
Gastric Cancer	xx%
Esophageal Squamous Cell Carcinoma	xx%
Small Cell Lung Cancer	xx%


**China PD-1 and PD-L1 Inhibitors Market by Treatment;
2018**




Treatment	Share
1L Treatment	xx%
2L+ Treatment	xx%

China PD-1 and PD-L1 Inhibitors Market: Treatment Analysis

China 1L PD-1 and PD-L1 Inhibitors Market by Value




China 2L+ PD-1 and PD-L1 Inhibitors Market by Value




Treatment	CAGR
	2018-2022
1L Treatment	xx%
2L+ Treatment	xx%

China PD-1 and PD-L1 Inhibitors Market: Cancer Analysis


China Non-small Cell Lung Cancer (NSCLC) Market by Value



China Hepatocellular Carcinoma (HCC) Market by Value




China Gastric Cancer (GC) Market by Value



Cancer	CAGR
	2018-2022
Non-small Cell Lung Cancer	xx%
Small Cell Lung Cancer	xx%
Hepatocellular Carcinoma	xx%
Gastric Cancer	xx%
Esophageal Squamous Cell Carcinoma	xx%

Global PD-1 and PD-L1 Inhibitors Market: Dynamics



Global PD-1 and PD-L1 Inhibitors Market: Competitive Landscape

Players Profiled

- Bristol-Myers Squibb
- Merck & Co., Inc.
- Roche
- AstraZeneca
- Jiangsu Hengrui Medicine Co. Ltd.
- BeiGene, Ltd.

Global PD-1 and PD-L1 Inhibitors Market Players by Phase
3 Studies; 2017

